

ViroLogic

[View the current ViroLogic Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/10863-ViroLogic.html)

(<http://www.bioportfolio.com/biocorporate/10863-ViroLogic.html>)

Contact Details:

270 East Grand Avenue

South San Francisco

CA

94080

United States of America

Tel:

Fax:

Email:

ViroLogic, a privately held South San Francisco-based biotechnology company, is a leader in the development of novel therapy guidance tools to enable patients, physicians, and medical reimbursers to make rational treatment decisions in the management of viral diseases. The company's proprietary technology is also being used in the fields of viral pharmacogenomics to identify, analyze, and select new drug candidates for treating viral diseases and cancer, and in disease management through the development of therapy guidance algorithms to guide patient therapy. ViroLogic sales representatives have been in the field since November 1999 raising awareness among HIV-treating physicians of phenotypic testing and its benefits.

Recent Publications by ViroLogic:



- [Assessing chemokine co-receptor usage in HIV.](#)
*PURPOSE OF REVIEW: HIV entry into cells is mediated through sequential...*30th April, 2005
ViroLogic Inc, South San Francisco, California 94080, USA.- *Curr Opin Infect Dis.* 2005 Feb;18(1):9-15.
- [Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1.](#)
*Wild-type viruses from the ViroLogic phenotype-genotype database were...*12th March, 2004
ViroLogic, Inc., South San Francisco, California 94080, USA.- *Antimicrob Agents Chemother.* 2004 Feb;48(2):437-43.
- [Polymorphisms in p1-p6/p6* of HIV type 1 can delay protease autoprocessing and increase drug susceptibility.](#)
*Maturation of infectious human immunodeficiency virus type 1 (HIV-1)...*12th December, 2003
ViroLogic, South San Francisco, California 94080, USA.- *AIDS Res Hum Retroviruses.* 2003 Sep;19(9):779-84. ([DOI Direct Link](#))
- [Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type](#)

[1 clinical isolates.](#)

*Nucleoside reverse-transcriptase inhibitors (NRTIs) are important...*5th November, 2003
ViroLogic, South San Francisco, California 94080, USA.- J Infect Dis. 2003 Oct 1;188(7):992-1000.
Epub 2003 Sep 16. ([DOI Direct Link](#))

- [Practical applications of viral fitness in clinical practice.](#)

*PURPOSE OF REVIEW: To review recent clinical data regarding viral fitness...*12th August, 2003
Division of Clinical Research, ViroLogic, Inc., San Francisco, CA 94080,- Curr Opin Infect Dis. 2003
Feb;16(1):11-8. ([DOI Direct Link](#))

- [Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance.](#)

*BACKGROUND: Current genotypic algorithms suggest that the HIV-1 protease...*24th June, 2003
ViroLogic, South San Francisco, California, USA.- AIDS. 2003 May 2;17(7):955-61.

- [Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.](#)

*Human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT)...*26th March, 2003
Gilead Sciences, Foster City, California 94404. ViroLogic, Inc., South San- Antimicrob Agents
Chemother. 2002 Nov;46(11):3437-46.

- [Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication.](#)

*Suboptimal treatment of human immunodeficiency virus type 1 (HIV-1)...*23rd January, 2003
Department of Research and Development, ViroLogic, Inc., South San- J Virol. 2003
Jan;77(2):1512-23.

- [Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.](#)

*OBJECTIVE: The routine use of phenotypic drug resistance testing in...*28th November, 2002
ViroLogic Inc, South San Francisco, California 94080, USA.- AIDS. 2002 Oct 18;16(15):F41-7.

- [Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information.](#)

*To determine the extent to which genotype (GT) or phenotype (PT) methods...*26th November, 2002
Virologic, Inc., South San Francisco, California 94080, USA.- J Acquir Immune Defic Syndr. 2002 Oct
1;31(2):128-36.

- [A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1.](#)

*Although combination antiretroviral therapy has resulted in a considerable...*8th May, 2000
ViroLogic, Inc., South San Francisco, California 94080, USA.- Antimicrob Agents Chemother. 2000
Apr;44(4):920-8.

Press Releases on ViroLogic:

[PDL BioPharma](#)

[Appoints Karen J.](#)

[Wilson as Vice](#)

[President, Finance and](#)

[Principal Accounting](#)

[Officer](#)

29th April, 2009

PDL BioPharma, Inc.

- Company Updates Board of
Directors Audit Committee Members
and Complies with Nasdaq Rule -
INCLINE VILLAGE, Nev., April 29
/PRNewswire-FirstCall/ -- PDL
BioPharma, Inc. (PDL) (Nasdaq:
PDLI) today

[Clinical Diagnostic Lab Testing Market to Grow Over 90% through 2017](#)

14th April, 2009

Washington G-2 Reports

Washington G-2 Reports releases 2009 Laboratory market projections. NEWARK, N.J., April 14 /PRNewswire/ -- A new study from market research firm Washington G-2 Reports indicates that the clinical

BioNews Results for ViroLogic



- [Father of sick boy develops oseltamivir-resistant H1N1](#)
New England Journal of Medicine: Nov 12 2009 2:26AM Matching: virologic
- [Nov 11 N Engl J Med letter](#)
New England Journal of Medicine: Nov 12 2009 2:26AM Matching: virologic
- [INCIDENCE OF VIROLOGIC ESCAPE OBSERVED DURING ITMN-191 \(R7227\) MONOTHERAPY IS GENOTYPE DEPENDENT, ASSOCIATED W](#)
National AIDS Treatment Advocacy Project: Nov 10 2009 3:31AM Matching: virologic
- [Kinetic Analysis Of Viral Rebound And Drug-resistant Viral Variant Dynamics In Patients Treated With Itmn-191](#)
National AIDS Treatment Advocacy Project: Nov 10 2009 3:31AM Matching: virologic
- [Telaprevir, Peginterferon Alfa-2a and Ribavirin Improved Rates of Sustained Virologic Response \(SVR\) in 'Diffi](#)
National AIDS Treatment Advocacy Project: Nov 10 2009 3:31AM Matching: virologic
- [Valeant Pharmaceuticals Highlights Taribavirin Phase IIb End of Study Data Presentation at American Associatio](#)
Pharma Live: Nov 6 2009 12:10AM Matching: virologic
- [High Sustained Virologic Response in Genotype 1 Null Responders to Peginterferon -2b + Ribavirin When Treated](#)
National AIDS Treatment Advocacy Project: Nov 5 2009 7:53AM Matching: virologic
- [Medical News: More Than 80 Percent Of HCV Genotype 1 Treatment-Naive Patients Achieved Sustained Virologic Response With Twice-Daily Telaprevir-Based Regimen](#)
Medical News Today: Nov 5 2009 1:36AM Matching: virologic
- [More Than 80 Percent Of HCV Genotype 1 Treatment-Naive Patients Achieved Sustained Virologic Response With Twi](#)
Medical News Today: Nov 5 2009 1:32AM Matching: virologic
- [Results from two Canadian studies confirm sustained viral response rates seen in hepatitis C patient](#)
Canada Free Press: Nov 4 2009 12:52PM Matching: virologic
- [Valeant Pharmaceuticals Highlights Taribavirin Phase IIb End of Study Data Presentation at American Associatio](#)
PR Newswire: Nov 3 2009 6:07PM Matching: virologic
- [Valeant Pharmaceuticals Highlights Taribavirin Phase IIb End of Study Data Presentation at American Association for the Study of Liver Disease \(AASLD\)](#)
Yahoo! Canada: Nov 3 2009 4:41PM Matching: virologic
- [Valeant Pharmaceuticals Highlights Taribavirin Phase IIb End of Study Data Presentation at American Associatio](#)
San Francisco Business Times: Nov 3 2009 1:46PM Matching: virologic
- [Valeant Pharmaceuticals Highlights Taribavirin Phase IIb End of Study Data Presentation at American](#)

Interest!ALERT: Nov 3 2009 1:32PM Matching: virologic

- [Results from two Canadian studies confirm sustained viral response rates seen in hepatitis C patients treated](#)

Therapeutics Daily: Nov 3 2009 5:50AM Matching: virologic

ViroLogic Clinical Trials:



- [TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 \(HIV-1\) Infected Patients With Nevirapine \(NVP\)](#)

ViroLogic Patents:



- 7037644- [Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS](#)
- 6942969- [Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening](#)
- 6869759- [Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS](#)
- 6653081- [Methods for monitoring antiretroviral therapy and guiding therapeutic decision in the treatment of HIV/AIDS](#)
- 6489098- [Means and methods for monitoring nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS](#)
- 6351690- [Automated method and system for performing antiviral drug susceptibility and resistance testing](#)
- 6242187- [Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening](#)
- 5837464- [Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core

information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

